GeneDx Holdings WGS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by GeneDx Holdings in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about GeneDx Holdings's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is GeneDx Holdings's cash & equivalents?
- GeneDx Holdings (WGS) reported cash & equivalents of $94.92M in Q1 2026.
- How has GeneDx Holdings's cash & equivalents changed year-over-year?
- GeneDx Holdings's cash & equivalents decreased by 5.7% year-over-year, from $100.69M to $94.92M.
- What is the long-term trend for GeneDx Holdings's cash & equivalents?
- Over 5 years (2020 to 2025), GeneDx Holdings's cash & equivalents has grown at a -2.3% compound annual growth rate (CAGR), from $118.96M to $105.99M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.